• In May 2026, Alkermes plc reported that it had presented new clinical and real-world evidence on its psychiatry portfolio, LYBALVI and ARISTADA, alongside sleep-medicine research across major U.S. psychiatric and health economics conferences, including APA, ISPOR, and others.
• A particularly important angle is Alkermes’ focus on real-world outcomes such as adherence, relapse proxies, and acute care use, which can influence how clinicians and payers view the practical value of LYBALVI versus standard olanzapine in schizophrenia and bipolar I disorder.
• We’ll now examine how this new real-world LYBALVI relapse and adherence data could reshape elements of Alkermes’ existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Alkermes Investment Narrative Recap

To own Alkermes, you have to believe its focused neuroscience portfolio, especially LYBALVI and ARISTADA, can support sustainable, clinically grounded growth while funding an expanding sleep-disorder pipeline. The new real-world LYBALVI data speak directly to that story but do not change the near term emphasis on executing psychiatry launches and managing rising R&D spend as the key catalyst and main risk.

The most relevant recent announcement is Alkermes’ May 12 update on positive Phase 3 REVITALYZ results for LUMRYZ in idiopathic hypersomnia, with plans for an sNDA filing by late 2026. Together with the new LYBALVI outcomes data, this reinforces that the near term investment focus sits at the intersection of commercial psychiatry performance and the clinical and regulatory progress of the sleep pipeline.

Yet, even as real-world outcomes look encouraging for LYBALVI, investors still need to think carefully about how rising R&D spend could...

Alkermes' narrative projects $2.1 billion revenue and $238.9 million earnings by 2029. This requires 11.8% yearly revenue growth and a $2.8 million earnings decrease from $241.7 million today.

Uncover how Alkermes' forecasts yield a $44.24 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected Alkermes to reach about US$2.6 billion in revenue and roughly US$779 million in earnings by 2029, so you should treat today’s LYBALVI data and sleep-pipeline updates as new information that might either support or challenge those ambitious assumptions.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.